AMAG Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$24.2M
Doctors Paid
24,580
Transactions
103,191
2024 Total
$327,779
Payment Breakdown by Category
Research$14.9M (61.8%)
Consulting$2.1M (8.5%)
Travel$685,535 (2.8%)
Food & Beverage$641,743 (2.7%)
Royalty/License$50,000 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.9M | 2,688 | 61.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 1,493 | 13.1% |
| Consulting Fee | $2.1M | 969 | 8.5% |
| Education | $1.3M | 84,081 | 5.3% |
| Grant | $942,413 | 39 | 3.9% |
| Travel and Lodging | $685,535 | 3,417 | 2.8% |
| Food and Beverage | $641,743 | 10,321 | 2.7% |
| Honoraria | $259,200 | 86 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $140,385 | 94 | 0.6% |
| Royalty or License | $50,000 | 1 | 0.2% |
| Gift | $180.00 | 2 | 0.0% |
Payments by Type
Research
$14.9M
2,688 transactions
General
$9.2M
100,503 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PRASTERONE DHEA FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER HSDD | $4.9M | 0 | 887 |
| HPC to reduce PTB in HIV-positive women in Zambia | $1.1M | 0 | 6 |
| Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone | $1.0M | 0 | 311 |
| INTRAVENOUS INFUSIONS OF FERUMOXYTOL COMPARED TO ORAL FERROUS SULFATE FOR THE TREATMENT OF ANEMIA IN PREGNANCY A RANDOMIZED CONTROLLED TRIAL | $795,276 | 0 | 3 |
| A MULTI-CENTER, RANDOMIZED, OPEN- LABEL STUDY COMPARING BIOAVAILABILITY WHEN PRESERVATIVE-FREE HYDROXYPROGESTERONE CAPROATE MAKENA IS ADMINISTERED AS A 1 ML TRAMUSCULAR IM INJECTION OR AS A XML SUBCUTANEOUS SC AUTO-INJECTION IN HEALTHY POST-MENOPAUSAL WOMEN | $769,016 | 0 | 37 |
| A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, SAFETY STUDY OF FERUMOXYTOL COMPARED TO FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IDA FIRM | $680,712 | 3 | 369 |
| A Phase 1, Randomized Study to Evaluate the Rate of Nausea in Healthy Premenopausal Female Subjects Treated With a Single Dose of Bremelanotide Alone or With Zofran | $628,833 | 0 | 3 |
| A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CIRAPARANTAG FOR REVERSAL OF ANTICOAGULATION IN HEALTHY ADULTS | $554,512 | 0 | 60 |
| Improving Pregnancy Outcomes with Progesterone - 2 IPOP-2 a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy | $441,297 | 0 | 1 |
| A PHASE 2B/3A, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF AMAG-423, A DIGOXIN IMMUNE FAB, IN ANTEPARTUM SUBJECTS WITH SEVERE PREECLAMPSIA | $392,968 | 0 | 122 |
| A Phase 2b3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia | $390,588 | 12 | 474 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA (IDA) IN PEDIATRIC SUBJECTS | $276,141 | 0 | 101 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain | $249,819 | 0 | 4 |
| IMPROVING PREGNANCY OUTCOMES WITH PROGESTERONE - 2 IPOP-2 A TRIAL OF 17-HYDROXYPROGESTERONE CAPROATE TO REDUCE PRETERM BIRTH AMONG WOMEN RECEIVING ANTIRETROVIRAL THERAPY IN PREGNANCY | $248,385 | 0 | 2 |
| Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy | $192,457 | 0 | 4 |
| Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT | $170,066 | 0 | 3 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA (IDA) IN PEDIATRIC SUBJECTS WITH CHRONIC KIDNEY DISEASE | $166,082 | 2 | 118 |
| Superiority and clinical value high res steady state CBV mapping using Ferumoxytol | $161,710 | 0 | 1 |
| A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MGML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPONTANEOUS PRETERM DELIVERY | $129,621 | 3 | 17 |
| PRASTERONE DHEA FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER HSDD - SECOND STUDY | $104,530 | 0 | 38 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IDA IN PEDIATRIC SUBJECTS WITH CHRONIC KIDNEY DISEASE | $104,170 | 0 | 43 |
| 17 HYDROXYPROGESTERONE CAPROATE SUPPLEMENTATION A NOVEL THERAPEUTIC FOR THE MANAGEMENT OF PREECLAMPSIA | $99,274 | 0 | 3 |
| Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients with Glioblastoma | $75,190 | 0 | 1 |
| The role of micro-RNA 223 in the pathogenesis of preeclampsia through interference with the epithelial-to-mesenchymal FBXW7 and Notchl-dependent transition of the extravillous trophoblast | $75,000 | 0 | 1 |
| The relationship of cervicovaginal microbiome to local inflammation, cervical length shortening, and ultrasound-indicated cerclage success | $75,000 | 0 | 1 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain and Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain | $69,593 | 0 | 1 |
| Open label Pilot Vulvoscopy Photography Study | $66,341 | 0 | 1 |
| OPEN LABEL PILOT VULVOSCOPY PHOTOGRAPHY STUDY | $66,341 | 0 | 2 |
| Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain and Efficacy and safety of Feraheme as a Magnetic Resonance Imaging (MRI) contrast agent to visualize lesions in the brain: confirmatory study | $58,008 | 0 | 1 |
| Metformin for Prevention of Hypertensive Disorders of Pregnancy in Women with Type 1 Diabetes Mellitus | $52,890 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| David Portman, Md, MD | Obstetrics & Gynecology | Columbus, OH | $300,674 | $0 |
| Dr. Amit Mehta, M.d, M.D | Hematology & Oncology | Cary, NC | $247,845 | $0 |
| Dr. James Simon, M.d, M.D | Reproductive Endocrinology | Washington, DC | $196,129 | $0 |
| Irwin Goldstein, Md, MD | Urology | San Diego, CA | $185,326 | $0 |
| Dr. Dennis Fisher, M.d, M.D | Contractor | San Francisco, CA | $178,923 | $0 |
| Ian Taras, Md, MD | Obstetrics & Gynecology | Woodland Hills, CA | $169,110 | $0 |
| Dr. John Fallon, M.d, M.D | Internal Medicine | Boston, MA | $168,164 | $0 |
| Unknown Provider | — | — | $129,573 | $0 |
| Diane Sutter, Md, MD | Gynecology | Kenmore, NY | $120,243 | $0 |
| Baha Sibai, M.d, M.D | Obstetrics & Gynecology | Houston, TX | $114,050 | $0 |
| Becky Lynn, Md, MD | Obstetrics & Gynecology | Saint Louis, MO | $109,281 | $0 |
| Michelle Owens, Md, MD | Obstetrics & Gynecology | Indianapolis, IN | $107,805 | $0 |
| Dr. Alan Fine, Md, MD | Obstetrics & Gynecology | Hartford, CT | $104,946 | $0 |
| Dr. Debra Wickman, Md, MD | Obstetrics & Gynecology | Phoenix, AZ | $103,350 | $0 |
| Andrew London, Md, MD | Gynecology | Lutherville, MD | $95,878 | $0 |
| Risa Kagan, M.d,, M.D, | Obstetrics & Gynecology | Berkeley, CA | $91,147 | $0 |
| Gloria Vigliani, M.d, M.D | Internal Medicine | Lexington, MA | $89,452 | $0 |
| Lee Shulman, Md, MD | Obstetrics & Gynecology | Chicago, IL | $88,409 | $0 |
| Dr. Scotty Hermann, Md, MD | Gynecology | Waco, TX | $80,152 | $0 |
| Dr. Suresh Ratnam, Md, MD | Medical Oncology | Mcallen, TX | $71,941 | $0 |
| Dr. Gregory Burkhart, M.d, M.D | Public Health & General Preventive Medicine | Reston, VA | $71,470 | $0 |
| Dr. Csanad Varallyay, M.d., Ph.d, M.D., PH.D | Diagnostic Radiology | Portland, OR | $69,181 | $0 |
| Anita Clayton, M.d, M.D | Psychiatry | Charlottesville, VA | $66,712 | $0 |
| Jack Ansell, M.d, M.D | Hematology | New York, NY | $64,332 | $0 |
| Dr. Mary Jane Minkin, M.d., Facog, M.D., FACOG | Obstetrics & Gynecology | New Haven, CT | $63,515 | $0 |
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. has made $24.2M in payments to 24,580 healthcare providers, recorded across 103,191 transactions in the CMS Open Payments database. In 2024, the company paid $327,779. The top product by payment volume is INTRAROSA ($10.2M).
Payments were distributed across 164 medical specialties. The top specialty by payment amount is Obstetrics & Gynecology ($3.4M to 12,525 doctors).
Payment categories include: Food & Beverage ($641,743), Consulting ($2.1M), Research ($14.9M), Travel & Lodging ($685,535), Royalties ($50,000).
AMAG Pharmaceuticals, Inc. is associated with 5 products in the CMS Open Payments database, including INTRAROSA, FERAHEME, and MAKENA.